1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH) / National Institute on Aging (NIA). Supports the establishment of a Data Coordinating Center focused on aging and Alzheimer's disease mouse brain atlases to advance systemic understanding of the aging brain and neurodegeneration.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Researchers/institutions in the USA; up to 5 years of funding. Confirm the full requirements in the official notice before applying.
Applications for Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Data Coordinating Center for the Aging and Alzheimer's Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) is funded by National Institutes of Health (NIH) / National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read articleR&D World's count of NIH RePORTER data shows 13,686 new awards in FY2026, up 21% from 11,272 in FY2025, while total extramural grants fell to about 56,600. New R01s hit 4,960. What the split means for FY2027 applicants.
Read article